What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
about
18 F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will playPreclinical Alzheimer disease: identification of cases at risk among cognitively intact older individualsBrain imaging in Alzheimer diseaseFluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatmentsAlzheimer's disease: Unique markers for diagnosis & new treatment modalitiesHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeBasal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.Neuronuclear imaging in the evaluation of dementia and mild decline in cognition.Multimodality imaging of Alzheimer disease and other neurodegenerative dementiasAlzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.Current and future uses of neuroimaging for cognitively impaired patients.Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms: an amygdaloid variant of Alzheimer disease.APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging.Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder.Estrogen: a master regulator of bioenergetic systems in the brain and bodyThree-Class Differential Diagnosis among Alzheimer Disease, Frontotemporal Dementia, and Controls.[Neuroimaging in Alzheimer's disease: a synthesis and a contribution to the understanding of physiopathological mechanisms].Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).Effects of age on the glucose metabolic changes in mild cognitive impairment.The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging.Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions.Differential diagnosis of neurodegenerative dementias using metabolic phenotypes on F-18 FDG PET/CT.Early detection of Alzheimer's disease using PiB and FDG PETProgression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's diseaseNeuroimaging in psychiatric disordersGlucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairmentA mitocentric view of Alzheimer's disease suggests multi-faceted treatmentsAssessment of mild dementia with amyloid and dopamine terminal positron emission tomographyEmerging biomarkers in cognition.Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairmentA survey of FDG- and amyloid-PET imaging in dementia and GRADE analysisImaging biomarkers associated with cognitive decline: a review.Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patientsNeuronal LRP1 regulates glucose metabolism and insulin signaling in the brainAlzheimer's disease: a clinical practice-oriented review.Evidence for ordering of Alzheimer disease biomarkersApplied multimodal diagnostics in a case of presenile dementia.The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease.
P2860
Q24186399-89B3FB3E-141C-46CE-A1D2-536988E2A1E1Q24594531-53FEC7D1-C979-4FA1-853F-93F644029825Q26995405-CD38379A-E357-4583-9454-D24D300E1C82Q26996299-B19F7BA8-56C5-45C3-8AE9-EC63B4E0ECBDQ27024117-5BCB9EB0-B631-49CC-A955-85741B4DD0DCQ28085139-1D421E93-5C9C-421B-8DF8-5F5B13DD1B67Q29614407-1577A92B-FD44-4015-B58E-1E6B807AE87CQ30436083-BE7A746E-2527-41AA-9A3D-3B7BCF6B98A5Q30571571-7DF4D83F-9D86-4154-B00D-369F2718A3E3Q30870819-7CA7BBD8-8D63-4247-A225-7528C3C41F48Q30996799-71F057F9-04A6-479F-B856-5EF0207236E6Q31143267-13E01C36-08E5-49E1-A297-18A985DD96D1Q33399386-006B9BE4-228A-44F0-B155-B50C4C79B05DQ33423191-E1361384-8700-4F2E-868A-A993251224A4Q33526779-F7E27A24-A9D1-4792-8DD3-A7EAF3166CC7Q33623924-DCEC3E06-E51E-461A-941B-13B0FD8CCBB3Q33633805-FF740FF0-0B3D-4485-A73F-11E757FF96D0Q33720033-8EA570A8-554C-42C8-B966-C648DAA00090Q33917702-40FFC7EF-68E3-4163-9E31-DE6A4AF1EFE0Q33931288-AFFFF774-E212-4CAE-A240-5577A17AFD3FQ34296479-62283D4A-7B55-4CBF-87A4-9FE7F370DC85Q34318022-8F3C7B90-8BDB-491B-B36B-ACBCE4065132Q34369575-9E291B09-F617-43A5-9CDB-BF28BD8949CCQ34483878-C307AA54-8C7E-4442-A9CB-F5D4052CDB63Q34606568-67ADC8C3-DBB3-4CE7-A467-D728E3DD7613Q34644697-CA1E57FF-078B-4419-AE67-CCCAD7561102Q34873370-3CFA4382-ADD7-4782-9398-6BADAFDF1D1FQ34902708-B7BEC53A-1356-493C-BE91-F340CD80658BQ35007862-571A42EC-86C3-4799-877A-7AE34E80E19EQ35008258-CAEF42FF-5C63-4212-B8F2-437EBAE0F854Q35120662-3B89EAB0-A8D6-4C92-A5C1-147AE89A2C11Q35158547-FE80C3F6-406B-4F95-AD73-507B653307CCQ35185786-DAB68CB5-F32A-467B-AEE0-8EFD34B60D20Q35194119-521EB1A2-5412-4394-8A15-76B73A5990F9Q35307950-2995C277-9DB1-4673-97E0-A704B3DBF8A5Q35899503-3C89AAB8-000B-42A5-AFAB-E8E29FC91A1FQ36071403-18CD9ECB-DE57-47EF-BC3A-CF21D8AC0A4EQ36099506-1F02DA8A-EF41-416E-9E1D-58E2F8C22138Q36306445-D6331700-DF53-4009-B6FF-FCD4EAFFBC5DQ36437623-1CB5C1E7-F2F0-481E-B150-E8B1890D9ECF
P2860
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
@en
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
@nl
type
label
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
@en
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
@nl
prefLabel
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
@en
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
@nl
P2093
P1433
P1476
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
@en
P2093
P304
P356
10.1212/01.WNL.0000269790.05105.16
P407
P577
2007-08-01T00:00:00Z